Eligo Bioscience to Present at Chardan’s 6th Annual Genetic Medicines Conference

September 27, 2022

Paris, France, September 27, 2022 – Eligo Bioscience, a preclinical-stage biotechnology developing first in class modalities to enable the targeted in vivo editing of genes from the microbiome, today announced that CEO Xavier Duportet will present a company overview at Chardan’s 6^th Annual Genetic Medicines Conference at 08:00 am ET on October 3, 2022.

The presentation will highlight Eligo’s novel and proprietary in vivo Gene Editing of the Microbiome platform (Gene Editing of the Microbiome), and how it can be used to address serious immune disorders with high unmet needs.

Chardan’s 6th Annual Genetic Medicines Conference is taking place October 3-4, 2022, in New York City and Xavier Duportet will be in attendance for the duration of the conference and available for one-to-one meetings. Use this link to find further information on the conference.

For more information about Eligo, visit https://www.eligo.bio/

Eligo Contact:
[email protected]